COMMUNIQUÉ DE PRESSE
News
-
-
COMMUNIQUÉ DE PRESSE
Amoéba and Koppert continue to prepare the commercial launch of AXPERA, the biocontrol product developed by Amoéba.
Amoéba to continue preparing for commercial launch of biocontrol solution AXPERA with Koppert, following successful authorisations. Company aims to meet market expectations for innovative biocontrol solutions -
-
COMMUNIQUÉ DE PRESSE
2024-2025 ANNUAL TURNOVER STABLE AT EUR 305.1 MILLION - 4TH QUARTER UP IN BOTH DIVISIONS
Oeneo Group reports a solid performance in Q4 with €83.3M turnover, up 3.8%. Full-year sales almost on par with previous year. Divisions see growth with Closures up 5.2% and Winemaking recovering -
COMMUNIQUÉ DE PRESSE
CHIFFRE D'AFFAIRES ANNUEL 2024-2025 STABLE A 305,1 M EUR - UN 4EME TRIMESTRE EN HAUSSE DANS LES 2 DIVISIONS
Le Groupe Oeneo annonce un chiffre d'affaires en hausse de +3,8% au 4e trimestre 2024. Bouchage progresse de 5,2%, Elevage de 9,5%. Prudence pour 2025-2026 dans le contexte du marché du vin -
COMMUNIQUÉ DE PRESSE
Oxurion Receives Transparency Notifications from Atlas Special Opportunities II LLC
Oxurion NV received transparency notifications regarding changes in shareholding percentages from Atlas Special Opportunities II, LLC. The biopharmaceutical company is focused on developing ophthalmic therapies for retinal disease -
COMMUNIQUÉ DE PRESSE
Oxurion ontvangt transparantiekennisgevingen van Atlas Special Opportunities II LLC
Oxurion NV ontvangt transparantiekennisgevingen van Atlas Special Opportunities II LLC over aandelentransacties en voldoet aan Belgische transparantiewetgeving. Het biofarmaceutisch bedrijf ontwikkelt oftalmologische therapieën -
-
-
